KR20130040524A - Liver protecting beverage containing blackberry vinegar and its preparing method - Google Patents
Liver protecting beverage containing blackberry vinegar and its preparing method Download PDFInfo
- Publication number
- KR20130040524A KR20130040524A KR1020110105353A KR20110105353A KR20130040524A KR 20130040524 A KR20130040524 A KR 20130040524A KR 1020110105353 A KR1020110105353 A KR 1020110105353A KR 20110105353 A KR20110105353 A KR 20110105353A KR 20130040524 A KR20130040524 A KR 20130040524A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- vinegar
- blackberry
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000052 vinegar Substances 0.000 title claims abstract description 43
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 43
- 235000013361 beverage Nutrition 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 16
- 210000004185 liver Anatomy 0.000 title claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 61
- 244000172730 Rubus fruticosus Species 0.000 claims abstract description 60
- 235000017848 Rubus fruticosus Nutrition 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000855 fermentation Methods 0.000 claims abstract description 28
- 230000004151 fermentation Effects 0.000 claims abstract description 28
- 239000012141 concentrate Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 18
- 239000000796 flavoring agent Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 14
- 235000019634 flavors Nutrition 0.000 claims abstract description 14
- 239000008213 purified water Substances 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 11
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 9
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 8
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 8
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 8
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 8
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 230000003908 liver function Effects 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- 241000589220 Acetobacter Species 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 abstract description 13
- 231100000234 hepatic damage Toxicity 0.000 abstract description 11
- 230000008818 liver damage Effects 0.000 abstract description 11
- 230000001681 protective effect Effects 0.000 abstract description 10
- 230000036542 oxidative stress Effects 0.000 abstract description 8
- 241000589234 Acetobacter sp. Species 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 abstract description 3
- 235000008504 concentrate Nutrition 0.000 abstract 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 235000019534 high fructose corn syrup Nutrition 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 235000021029 blackberry Nutrition 0.000 description 45
- 241000700159 Rattus Species 0.000 description 23
- 231100000304 hepatotoxicity Toxicity 0.000 description 22
- 230000007056 liver toxicity Effects 0.000 description 18
- 230000001154 acute effect Effects 0.000 description 16
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- 108010082126 Alanine transaminase Proteins 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- -1 superoxide radicals Chemical class 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000013417 toxicology model Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000544066 Stevia Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000010240 hepatic drug metabolism Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12J—VINEGAR; PREPARATION OR PURIFICATION THEREOF
- C12J1/00—Vinegar; Preparation or purification thereof
- C12J1/04—Vinegar; Preparation or purification thereof from alcohol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/02—Acetobacter
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 블랙베리 식초를 유효성분으로 함유하는 간 기능 개선용 음료 조성물 및 이의 제조방법에 관한 것이다.
The present invention relates to a beverage composition for improving liver function and a method for preparing the same, containing blackberry vinegar as an active ingredient.
슈퍼옥사이드 라디칼(superoxide radical), 과산화수소 및 하이드록실라디칼(hydroxyl radical)과 같은 활성 산소종(Reactive oxygen species, ROS)은 제노바이오틱스(xenobiotics), 약물, 중금속, 자외선(UV), 및 이온화방사선(ionizing radiation)과 같은 다양한 인자에 의해서 유도된다. 비록, ROS가 정상 생리학적 상태에서 중요한 역할을 담당하지만, 높은 수준의 ROS는 단백질, 지질 및 DNA와 같은 다양한 세포의 생물분자에 손상을 유발시키며(Kaspar, J.W., et al., Free Radical Biology and Medicine , 2009), 노화, 암, 죽상동맥경화증(atherosclerosis), 당뇨 및 퇴행성 뇌질환과 연관되어 왔다(Wiseman, H., et al., Biochemical Journal, 1996). 살아있는 유기체는 ROS 형성을 방지하거나 또는 ROS를 무독화시키기 위한 다양한 기작을 발달시켜왔다. 이러한 기작은 과산화물제거효소(superoxide dismutase, SOD), 카탈라아제(CAT, catalase) 및 글루타티온 페옥사이드(glutathione peroxidase, GPx)와 같은 항산화 효소 및 글루타티온(glutathione, GSH), 요산(uric acid), 및 비타민 C 및 E와 같은 비효소 항산화물질이 관련된다(Issa, A.Y., et al., Journal of Food Composition and Analysis, 2006; Mohammadi, M. et al., Food and Chemical Toxicology, 2009).
Reactive oxygen species (ROS), such as superoxide radicals, hydrogen peroxide and hydroxyl radicals, are known as xenobiotics, drugs, heavy metals, ultraviolet (UV), and ionizing radiation ( induced by various factors such as ionizing radiation. Although ROS play an important role in normal physiological conditions, high levels of ROS cause damage to biomolecules of various cells such as proteins, lipids and DNA (Kaspar, JW, et al., Free Radical Biology and Medicine , 2009), has been associated with aging, cancer, atherosclerosis, diabetes and degenerative brain diseases (Wiseman, H., et al., Biochemical Journal , 1996). Living organisms have developed a variety of mechanisms to prevent ROS formation or to detoxify ROS. These mechanisms include antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT, catalase) and glutathione peroxide (GPx), and glutathione (GSH), uric acid, and vitamin C. And nonenzymatic antioxidants such as E (Issa, AY, et al., Journal of Food Composition and Analysis , 2006; Mohammadi, M. et al., Food and Chemical Toxicology , 2009).
블랙베리(blackberry)(Rubus fruticosus L.)는 우수한 천연 항산화제로서, 다양한 치료 목적으로 사용되어 왔다. 근래의 연구에서 블랙베리는 암 및 심혈관 질환의 위험을 감소시킬 수 있다는 것이 밝혀졌다(Cuevas-Rodriguez et al., 2010a). 블랙베리는 안토시아닌(anthocyanin)과 플라보놀(flavonol), 페놀산(phenolic acid), 엘라그산(ellagic acid), 비타민 C 및 E와 같은 다른 항산화물질을 다량 포함하고 있다고 알려졌다(Bowen-Forbes, C.S., et al., Journal of Food Composition and Analysis , 2010). 블랙베리의 주요 폴리페놀(polyphenolic) 화합물인 안토시아닌(anthocyanin)은 슈퍼옥사이드 라디칼(superoxide radical), 과산화수소 및 하이드록실라디칼(hydroxyl radical)과 같은 다양한 ROS의 스캐빈저(scavenger)이다(Cuevas-Rodriguez et al., Journal of Agricultural and Food Chemistry, 58, 9542-9548, 2010). 다양한 연구에서 항산화 물질 및/또는 항염증제로서의 잠재적인 생물학적 이점에 대해서 보고된바 있다(Hassimotto, N.M.A., et al., Journal of the Science of Food and Agriculture , 2010). 그러나, 블랙 베리의 간기능 개선에 대한 기능적 역할에 대해서 알려진 바가 매우 적다.
Blackberry ( Rubus fruticosus L. ) is an excellent natural antioxidant and has been used for various therapeutic purposes. Recent studies have shown that blackberries can reduce the risk of cancer and cardiovascular disease (Cuevas-Rodriguez et al., 2010a). Blackberries are known to contain high amounts of other antioxidants such as anthocyanin, flavonol, phenolic acid, ellagic acid, vitamins C and E (Bowen-Forbes, CS, et al., Journal of Food Composition and Analysis , 2010). Antocyanin, BlackBerry's main polyphenolic compound, is a scavenger of various ROS such as superoxide radicals, hydrogen peroxide and hydroxyl radicals (Cuevas-Rodriguez et. al., Journal of Agricultural and Food Chemistry , 58, 9542-9548, 2010). Various studies have reported on potential biological benefits as antioxidants and / or anti-inflammatory agents (Hassimotto, NMA, et al., Journal of the Science of Food and Agriculture , 2010). However, little is known about the functional role of BlackBerry in improving liver function.
CCl4(carbon tetrachloride)는 대표적인 급성 간 독성 유발 물질로 현재까지 CCl4의 정확한 작용기전은 알려져 있지 않으나 체내로 흡수된 CCl4가 간장 내 약물대사 효소계에 의해 CCl3(trichloromethyl radical)로 대사되어 세포막의 지질과산화를 초래하여 막의 구조와 기능을 파괴함으로써 간 세포 손상을 유발하는 것으로 알려져 있다. 또한 세포막의 구조와 기능이 파괴되게 되면 간 세포질 내에 널리 존재하는 효소인 알라닌 아미노전이효소(Alanine Aminotransferase, ALT) 및 아스파진산 아미노전이효소(Aspartate Aminotransferase, AST)가 혈액으로 유출되므로 혈액 내 ALT 및 AST 수치는 간 손상의 지표로 빈번히 사용되고 있다.
CCl 4 (carbon tetrachloride) is a representative acute liver toxicity inducer. To date, the exact mechanism of action of CCl 4 is unknown, but CCl 4 is absorbed into the body and metabolized to CCl 3 (trichloromethyl radical) by the hepatic drug metabolism enzyme system. It is known to cause liver cell damage by destroying the structure and function of the membrane by causing lipid peroxidation. In addition, when the structure and function of cell membranes are destroyed, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST), which are widely present in liver cytoplasm, are leaked into the blood. Levels are frequently used as indicators of liver damage.
이에, 본 발명자들은 간 손상을 유발시킬 수 있는 CCl4 처리에 의해서 유도된 급성 간 독성 모델에 본 발명에 따른 블랙베리 식초를 함유하는 음료 조성물을 처리하였을 때, 항산화 효소인 GPx의 활성을 증가시키고, 간 손상 지표인 아미노전이효소(Alanine Aminotransferase, ALT) 및 아스파진산 아미노전이효소(Aspartate Aminotransferase, AST) 수치를 현저히 감소시키므로, 간기능 개선에 효과적으로 사용 수 있음을 확인함으로써, 본 발명을 완성하였다.
Accordingly, the present inventors have increased the activity of the antioxidant enzyme GPx when treating a beverage composition containing the blackberry vinegar according to the present invention in an acute liver toxicity model induced by CCl 4 treatment that can cause liver damage. The present invention was completed by confirming that amino acid transferase (ALT) and aspartic acid aminotransferase (AST), which are indicators of liver damage, can be effectively used to improve liver function.
본 발명의 목적은 블랙베리(Rubus fruticosus L.) 식초를 함유하는 간기능 개선용 음료 조성물 및 이의 제조방법을 제공하는 것이다.
An object of the present invention is a BlackBerry ( Rubus) fruticosus L. ) It is to provide a beverage composition for improving liver function containing vinegar and a method for producing the same.
상기 목적을 달성하기 위하여, 본 발명은In order to achieve the above object,
1) 블랙베리 식초 4 내지 10 중량부, 블랙베리 농축액 0.5 내지 3 중량부, 사과농축액 0.5 내지 3 중량부, 액상과당 6 내지 15 중량부, 플락토 올리고당 1 내지 5 중량부, 효소처리 스테비아 0.001 내지 0.020 중량부, 구연산 0.1 내지 0.5 중량부, 연잎추출물 0.01 내지 0.1 중량부, 라즈베리 향료 0.01 내지 0.1 중량부 및 정제수 70 내지 90 중량부를 혼합하여 교반하는 단계;1) 4 to 10 parts by weight of blackberry vinegar, 0.5 to 3 parts by weight of blackberry concentrate, 0.5 to 3 parts by weight of apple concentrate, 6 to 15 parts by weight of liquid fructose, 1 to 5 parts by weight of flacto oligosaccharide, 0.001 to 1 part of enzyme treatment stevia Stirring by mixing 0.020 parts by weight, citric acid 0.1-0.5 parts by weight, lotus leaf extract 0.01-0.1 parts by weight, raspberry flavor 0.01-0.1 parts by weight and purified water 70-90 parts by weight;
2) 상기 단계 1)의 혼합하여 교반된 액을 여과하는 단계;2) filtering the stirred liquid by mixing of step 1);
3) 단계 2)의 여과된 액을 살균한 후, 여과하는 단계를 포함하는 블랙베리 식초를 함유하는 간 기능 개선용 음료 조성물의 제조방법을 제공한다.3) After sterilizing the filtrate of step 2), and provides a method for producing a beverage composition for improving liver function containing blackberry vinegar comprising the step of filtration.
또한, 본 발명은 본 발명의 제조방법에 의해 제조된 블랙베리 식초를 함유하는 간 기능 개선용 음료 조성물을 제공한다.
In addition, the present invention provides a beverage composition for improving liver function containing blackberry vinegar produced by the production method of the present invention.
본 발명의 블랙베리 식초를 함유하는 음료 조성물은 간 독성을 유발한다고 알려진 CCl4 처리에 의해서 유도된 급성 간 독성 모델에서 산화 스트레스에 대한 보호효과 및 간 손상을 회복시키는 효과를 보이므로, 간 기능 개선용 건강보조식품으로 유용하게 이용될 수 있다.
The beverage composition containing the blackberry vinegar of the present invention has a protective effect against oxidative stress and restores liver damage in acute liver toxicity model induced by CCl 4 treatment known to cause liver toxicity, thereby improving liver function. It can be usefully used as a dietary supplement for health.
도 1은 초산발효(acetic acid fermentation) 동안 산도(Titratable acidity) 및 알코올 함량(Alcohol content)을 측정한 결과를 나타낸 도이다.
도 2는 본 발명의 음료 조성물의 CCl4 유도 급성 간 독성 랫트에서의 항산화 효소 GPx 활성 증가 효과를 나타낸 도이다;
#: 대조군에 대하여, p<0.05; 및
*: CCl4 처리군에 대하여, p<0.05;
도 3은 본 발명의 음료 조성물의 CCl4 유도 급성 간 독성 랫트에서의 간 보호효과를 측정한 그래프이다.
도 3의 A는 본 발명의 음료 조성물의 CCl4 처리에 의하여 유도된 간 손상의 회복을 혈청내 아르파라진산 아미노전이효소(Aspartate Aminotransferase, AST) 수준을 통하여 확인한 그래프이다:
#: 대조군에 대하여, p<0.001;
*: CCl4 처리군에 대하여, p<0.05; 및
**: CCl4 처리군에 대하여, p<0.01.
도 3의 B는 본 발명의 음료 조성물의 CCl4 처리에 의하여 유도된 간 손상의 회복을 혈청내 알라닌 아미노전이효소(Alanine Aminotransferase, ALT) 수준을 통하여 확인한 그래프이다:
#: 대조군에 대하여, p<0.001; 및
**: CCl4 처리군에 대하여, p<0.01.1 is a view showing the results of measuring the acidity (Titratable acidity) and alcohol content (Alcohol content) during acetic acid fermentation (acetic acid fermentation).
2 is a diagram showing the effect of increasing the antioxidant enzyme GPx activity in CCl 4 induced acute liver toxicity rats of the beverage composition of the present invention;
#: For control, p <0.05; And
*: P <0.05 for CCl 4 treatment group;
Figure 3 is a graph measuring the protective effect of liver in CCl 4 induced acute liver toxicity rats of the beverage composition of the present invention.
Figure 3 A is a graph confirming the recovery of liver damage induced by CCl 4 treatment of the beverage composition of the present invention through the level of Aspartate Aminotransferase (AST) in serum:
#: For control, p <0.001;
*: P <0.05 for CCl 4 treatment group; And
**: p <0.01 for CCl 4 treatment group.
3B is a graph confirming the recovery of liver damage induced by CCl 4 treatment of the beverage composition of the present invention through serum alanine Aminotransferase (ALT) levels:
#: For control, p <0.001; And
**: p <0.01 for CCl 4 treatment group.
이하 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은,According to the present invention,
1) 블랙베리 식초 4 내지 10 중량부, 블랙베리 농축액 0.5 내지 3 중량부, 사과농축액 0.5 내지 3 중량부, 액상과당 6 내지 15 중량부, 플락토 올리고당 1 내지 5 중량부, 효소처리 스테비아 0.001 내지 0.020 중량부, 구연산 0.1 내지 0.5 중량부, 연잎추출물 0.01 내지 0.1 중량부, 라즈베리 향료 0.01 내지 0.1 중량부 및 정제수 70 내지 90 중량부를 혼합하여 교반하는 단계;1) 4 to 10 parts by weight of blackberry vinegar, 0.5 to 3 parts by weight of blackberry concentrate, 0.5 to 3 parts by weight of apple concentrate, 6 to 15 parts by weight of liquid fructose, 1 to 5 parts by weight of flacto oligosaccharide, 0.001 to 1 part of enzyme treatment stevia Stirring by mixing 0.020 parts by weight, citric acid 0.1-0.5 parts by weight, lotus leaf extract 0.01-0.1 parts by weight, raspberry flavor 0.01-0.1 parts by weight and purified water 70-90 parts by weight;
2) 상기 단계 1)의 혼합하여 교반된 액을 여과하는 단계;2) filtering the stirred liquid by mixing of step 1);
3) 단계 2)의 여과된 액을 살균한 후, 여과하는 단계를 포함하는 블랙베리 식초를 함유하는 간 기능 개선용 음료 조성물의 제조방법을 제공한다.3) After sterilizing the filtrate of step 2), and provides a method for producing a beverage composition for improving liver function containing blackberry vinegar comprising the step of filtration.
본 발명의 제조방법에 있어서, 상기 블랙베리는 재배한 것 또는 시판되는 것을 제한 없이 사용할 수 있다.In the production method of the present invention, the blackberry may be used without limitation, those grown or commercially available.
본 발명의 제조방법에 있어서, 상기 블랙베리 농축액 또는 사과 농축액은 1) 세척하는 단계, 2) 착즙하는 단계, 3) 여과하는 단계. 4) 농축하는 단계, 5) 살균하는 단계를 포함하는 방법에 의해 제조한 것, 시판되는 것 또는 당해 기술분야에서 통상적으로 행하는 방법에 의해 제조하여 사용할 수 있으나 이에 한정되지 않는다.In the preparation method of the present invention, the blackberry concentrate or apple concentrate is 1) washing step, 2) juice step, 3) filtration step. It may be prepared by a method including a step of concentrating, 5) sterilization, commercially available or prepared by a method commonly used in the art, but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 연잎 추출물은 하기의 단계들을 포함하는 제조방법 또는 시판되는 것 또는 당해 기술분야에서 통상적으로 행하는 방법에 의해 제조하여 사용할 수 있으나 이에 한정되지 않는다:In the production method of the present invention, the lotus leaf extract may be prepared and used by a production method or a commercially available method including the following steps or a method commonly performed in the art, but is not limited thereto.
1) 연잎에 추출용매를 가하여 추출하는 단계;1) extracting by adding an extraction solvent to the lotus leaf;
2) 단계 1)의 추출물을 여과하는 단계; 및2) filtering the extract of step 1); And
3) 단계 2)의 여과한 추출물을 감압농축한 후 건조하는 단계. 3) Concentrating the filtered extract of step 2) under reduced pressure and drying.
본 발명의 제조방법에 있어서, 상기 라즈베리 향료는 제조한 것 또는 당해 기술분야에서 통상적으로 행하는 방법에 의해 제조하여 사용할 수 있으나 이에 한정되지 않는다.In the production method of the present invention, the raspberry flavor may be prepared or used by a method commonly performed in the art, but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 정제수는 RO(reverse osmosis) 여과기를 통해 정제하는 것이 바람직하나 이에 한정되지 않는다In the production method of the present invention, the purified water is preferably purified through a reverse osmosis (RO) filter, but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 단계 1)의 교반은 바람직하게는 45 내지 55℃, 보다 바람직하게는 50 내지 53℃에서 바람직하게는 20 내지 40 분간, 보다 바람직하게는 30 내지 35 분간 실시하는 것이 바람직하나 이에 한정되지 않는다. In the production method of the present invention, the stirring in the step 1) is preferably performed at 45 to 55 ° C, more preferably at 50 to 53 ° C, preferably for 20 to 40 minutes, and more preferably for 30 to 35 minutes. But is not limited thereto.
본 발명의 제조방법에 있어서, 상기 여과는 바람직하게는 3 내지 7 μ, 보다 바람직하게는 5 내지 6 μ필터로 실시하는 것이 바람직하나 이에 한정되지 않는다. In the production method of the present invention, the filtration is preferably performed with a 3 to 7 μm, more preferably a 5 to 6 μm filter, but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 살균은 63℃ 내지 65℃에서 약 30분간 살균하는 저온장시간 살균법(Low temperature long time, LTLT), 90℃ 내지 110℃에서 15 내지 30초간 살균하는 고온단시간살균법(High temperature short time, HTST) 및 120℃ 내지 150℃에서 1 내지 3초간 살균하는 초고온순간살균법(Ultra high temperature, UHT) 등으로 수행할 수 있으며, 원료의 갈변현상을 최소화하면서 오염세균을 최대한 살균시키기 위하여, 98℃에서 30 초간 살균하는 것이 가장 바람직하나 이에 한정되지 않는다. In the preparation method of the present invention, the sterilization is a low temperature long time (LTLT) sterilization for about 30 minutes at 63 ℃ to 65 ℃, high temperature short time sterilization for 15 to 30 seconds sterilization at 90 ℃ to 110 ℃ Method (Ultra high temperature short time, HTST) and ultra high temperature (UHT) to sterilize for 1 to 3 seconds at 120 ℃ to 150 ℃, and can be carried out by minimizing browning of raw materials In order to sterilize as much as possible, sterilization at 98 ° C. for 30 seconds is most preferred but not limited thereto.
본 발명의 제조방법에 있어서, 상기 단계 3)이후에 80 내지 95℃가 유지되도록 용기에 충진하고 냉각기에서 35 내지 50℃ 까지 냉각시키는 단계를 추가적으로 포함할 수 있으나, 이에 한정되지 않는다. 또한, 상기 용기의 재질은 폴리프로필렌 수지, 폴리에틸렌 수지 등 음료 용기의 재질로 사용될 수 있는 것이면 어떠한 것이든 무방하고, 용기의 형태는 파우치백이나 캔, 병등을 사용하는 것이 바람직하나 이에 한정되지 않는다.
In the manufacturing method of the present invention, after the step 3) may be further included in the container to maintain 80 to 95 ℃ and cooled to 35 to 50 ℃ in the cooler, but is not limited thereto. In addition, the material of the container may be any material as long as it can be used as a material of a beverage container such as polypropylene resin, polyethylene resin, and the shape of the container is preferably a pouch bag, a can, or a bottle, but is not limited thereto.
본 발명의 제조방법에 있어서, 상기 단계 1)의 블랙베리 식초는 하기의 단계로 제조되는 것이 바람직하나 이에 한정되지 않는다.In the production method of the present invention, the blackberry vinegar of step 1) is preferably prepared by the following steps, but is not limited thereto.
a) 블랙베리 파쇄액 25 내지 35 중량부 바람직하게는 30 중량부, 사과농축액 10 내지 20 중량부 바람직하게는 16.6 중량부 및 정제수 50 내지 60 중량부 바람직하게는 53.4 중량부를 혼합하여 초기 당도를 10 내지 20°brix으로 조정하고 효모를 접종하여 알코올 발효시키는 단계; 및 a) 25 to 35 parts by weight of black crushed liquor, preferably 30 parts by weight, 10 to 20 parts by weight of apple concentrate, preferably 16.6 parts by weight, and 50 to 60 parts by weight of purified water, preferably 53.4 parts by weight, to obtain an initial sugar content of 10 Adjusting to 20 ° brix and inoculating yeast for alcohol fermentation; And
b) 상기 단계 1)의 알코올 발효물은 여과한 후, 알코올 농도 5 내지 9%로 조정하고 초산균을 접종하여 초산 발효시키는 단계.b) the alcohol fermentation of step 1) is filtered, and then adjusted to an alcohol concentration of 5 to 9% and inoculated with acetic acid bacteria to ferment acetic acid.
상기 초기당도는 너무 낮으면 최종 알코올 농도가 감소하고, 너무 높으면 알코올 발효가 지연되거나 진행되지 않으므로 13 내지 18°brix인 것이 바람직하고, 15 내지 16°brix인 것이 보다 바람직하나 이에 한정되지 않는다.If the initial sugar is too low, the final alcohol concentration is reduced, if too high alcohol fermentation is not delayed or advanced, it is preferably 13 to 18 ° brix, more preferably 15 to 16 ° brix, but is not limited thereto.
상기 단계 a)의 알코올 발효는 효모를 접종하여 일정시간 발효시키는데, 이러한 효모는 피처리물 전체 중량을 100으로 하여 건조 중량으로 바람직하게 1 내지 10 중량부, 보다 바람직하게는 5 중량부를 접종하여 효모의 생육온도 범위, 바람직하게는 20 내지 30℃, 보다 바람직하게는 25℃에서, 바람직하게는 2일 내지 6일, 보다 바람직하게는 4일 동안 발효하는 것이 바람직하나 이에 한정되지 않는다. Alcohol fermentation of step a) is inoculated with yeast for a certain time, such yeast is preferably 1 to 10 parts by weight, more preferably 5 parts by weight in dry weight with a total weight of the workpiece to be 100 It is preferable to ferment for a growth temperature range of, preferably 20 to 30 ℃, more preferably 25 ℃, preferably 2 days to 6 days, more preferably 4 days, but is not limited thereto.
또한, 상기 효모는 식용가능한 다양한 효모를 사용할 수 있으며, 사카로미세스 세레비시아(Saccharomyces cerevisiae; KCTC 7904) 또는 사카로미세스 보야뉴스(Saccharomyces boyanus)인 것이 바람직하고, 사카로미세스 세레비시아(Saccharomyces cerevisiae; KCTC 7904)인 것이 보다 바람직하나 이에 한정되지 않는다.In addition, the yeast may use a variety of edible yeast, Saccharomyces cerevisiae ; KCTC 7904) or Saccharomyces boyanus , and Saccharomyces cerevisiae ; KCTC 7904), but is not limited thereto.
상기 단계 b)의 알코올 농도는 바람직하게는 5 내지 9%로, 보다 바람직하게는 7 내지 8%, 가장 바람직하게는 7.4%로 조정하는 것이 바람직하나 이에 한정되지 않는다. Preferably, the alcohol concentration of step b) is adjusted to 5-9%, more preferably 7-8%, and most preferably 7.4%, but is not limited thereto.
상기 단계 b)의 초산 발효는 아세토박터 종. PA 97(Acetobacter sp . PA 97)을 바람직하게는 5 내지 20 중량부, 보다 바람직하게는 10 중량부를 접종하고 바람직하게는 25 내지 35℃, 보다 바람직하게는 35℃에서 바람직하게는 10일 내지 25일, 보다 바람직하게는 20일 배양하는 것이 바람직하나 이에 한정되지 않는다.Acetic acid fermentation of step b) is acetobacter species. PA 97 ( Acetobacter sp . PA 97) is preferably inoculated at 5 to 20 parts by weight, more preferably at 10 parts by weight, preferably at 25 to 35 ° C, more preferably at 35 ° C, preferably 10 to 25 days, more preferably It is preferable to
상기 단계 b)의 있어서 초산 발효는 초기 산도를 바람직하게는 0.5 내지 2% 범위, 보다 바람직하게는 1 내지 1.5%로 조정하여 이루어지는 것이 바람직하나 이에 한정되지 않는다.
Acetic acid fermentation in step b) is preferably made by adjusting the initial acidity to 0.5 to 2% range, more preferably 1 to 1.5%, but is not limited thereto.
본 발명의 구체적인 실시예에서, 블랙베리 식초를 포함하는 음료 조성물을 제조하기 위하여, 1)의 블랙베리 식초 4 내지 10 중량부, 블랙베리 농축액 0.5 내지 3 중량부, 사과농축액 0.5 내지 3 중량부, 액상과당 7 내지 12 중량부, 플락토 올리고당 1 내지 5 중량부, 효소처리 스테비아 0.005 내지 0.015 중량부, 구연산 0.1 내지 0.5 중량부, 연잎추출물 0.01 내지 0.1 중량부, 라즈베리 향료 0.01 내지 0.1 중량부 및 정제수 70 내지 90 중량부를 혼합하여 교반하는 단계; 2) 상기 단계 1)의 혼합하여 교반된 액을 여과하는 단계; 3) 단계 2)의 여과된 액을 살균한 후, 여과하는 단계를 포함하는 블랙베리 식초를 포함하는 간 기능 개선용 음료 조성물을 제조하였다(도 1 및 표 1 참조).In a specific embodiment of the present invention, in order to prepare a beverage composition comprising blackberry vinegar, 4 to 10 parts by weight of blackberry vinegar, 0.5 to 3 parts by weight of blackberry concentrate, 0.5 to 3 parts by weight of apple concentrate, 7 to 12 parts by weight of liquid fructose, 1 to 5 parts by weight of flacto oligosaccharide, 0.005 to 0.015 parts by weight of enzymatically treated stevia, 0.1 to 0.5 parts by weight of citric acid, 0.01 to 0.1 parts by weight of lotus leaf extract, 0.01 to 0.1 parts by weight of raspberry flavor and purified water Stirring by mixing 70 to 90 parts by weight; 2) filtering the stirred liquid by mixing of step 1); 3) After sterilizing the filtrate of step 2), to prepare a beverage composition for improving liver function comprising the black vinegar comprising the step of filtration (see Fig. 1 and Table 1).
본 발명의 구체적인 실시예에서, CCl4 처리에 의해서 유도된 급성 간 독성 모델에서 산화스트레스에 대한 보호효과를 확인한 결과, 본 발명의 음료 조성물을 미리 투여한 후, CCl4를 투여하여 제조한 간 독성 랫트에서는 GPx의 활성이 대조군에 비하여 유의하게 증가하는 것을 확인하였다(도 2).In a specific embodiment of the present invention, as a result of confirming the protective effect against oxidative stress in acute liver toxicity model induced by CCl 4 treatment, hepatotoxicity prepared by administering CCl 4 after pre-administration of the beverage composition of the present invention In rats, the activity of GPx was significantly increased compared to the control (Fig. 2).
본 발명의 구체적인 실시예에서, CCl4 처리에 의해서 유도된 급성 간 독성 모델 간 보호효과를 확인한 결과, 본 발명에 따른 음료 조성물(3 또는 6 ㎖/㎏)을 미리 투여한 후, CCl4를 투여하여 제조한 간 독성 랫트에서는 AST와 ALT의 수준이 현저하게 감소하는 것을 확인하였다(도 3).In a specific embodiment of the present invention, acute liver toxicity model induced by CCl 4 treatment confirmed that the liver protective effect, after administering the beverage composition (3 or 6 ml / kg) according to the invention in advance, and then administered CCl 4 In liver hepatotoxic rats prepared, the levels of AST and ALT were significantly reduced (FIG. 3).
따라서, 본 발명의 블랙베리 식초를 함유하는 음료 조성물은 간 독성을 유발한다고 알려진 CCl4 처리에 의해서 유도된 급성 간 독성 모델에서 산화 스트레스에 대한 보호효과 및 간 손상을 회복시키는 효과를 보이므로, 간 기능 개선용 건강기능식품 또는 건강보조식품으로 유용하게 이용될 수 있다.
Therefore, the beverage composition containing the blackberry vinegar of the present invention shows a protective effect against oxidative stress and restores liver damage in acute liver toxicity model induced by CCl 4 treatment, which is known to cause liver toxicity. It can be usefully used as a functional food or health supplement for improving function.
본 발명의 음료 조성물은 필수 성분으로서 상기 원료들을 지시된 비율로 함유하는 외에, 액체성분에는 특별한 제한 점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. The beverage composition of the present invention contains, as essential ingredients, the above-mentioned raw materials in the ratios indicated, and there is no particular limitation on the liquid component, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
상기 추가성분으로는 베타시클로덱스트린 0.05~0.2 중량부, 및 L-아스파라긴, 비타민 B1, 비타민 B2, 글리신, 카라멜색소, 수크랄로스, 안식향산나트륨 및 드링크향으로 이루어진 군으로부터 선택된 첨가물 0.002~0.1 중량부을 함유하는 것이 바람직하나 이에 한정되지 않는다.The additional component contains 0.05 to 0.2 parts by weight of betacyclodextrin, and 0.002 to 0.1 parts by weight of an additive selected from the group consisting of L-asparagine, vitamin B1, vitamin B2, glycine, caramel pigment, sucralose, sodium benzoate and drink flavor. But is not limited thereto.
즉, 상기 추가성분 외에 천연 탄수화물로서 모노사카라이드, 디사카라이드, 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜 등을 사용할 수 있고, 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등) 등을 사용할 수 있으나 이에 한정되지 않는다. That is, in addition to the above additional components, as a natural carbohydrate, conventional sugars such as monosaccharides, disaccharides, polysaccharides, for example, dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol can be used. As the flavoring agent, natural flavoring agents (tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used, but are not limited thereto.
상기 추가성분 외에 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.
In addition to the above additional ingredients, various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof, organic acids , Protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
또한, 본 발명은 본 발명의 제조방법에 의해 제조된 블랙베리 식초를 함유하는 간 기능 개선용 음료 조성물을 제공한다. In addition, the present invention provides a beverage composition for improving liver function containing blackberry vinegar produced by the production method of the present invention.
본 발명의 블랙베리 식초를 함유하는 음료 조성물은 간 독성을 유발한다고 알려진 CCl4 처리에 의해서 유도된 급성 간 독성 모델에서 산화 스트레스에 대한 보호효과 및 간 손상을 회복시키는 효과를 보이므로, 간 기능 개선용 건강기능식품 또는 건강보조식품으로 유용하게 이용될 수 있다.
The beverage composition containing the blackberry vinegar of the present invention has a protective effect against oxidative stress and restores liver damage in acute liver toxicity model induced by CCl 4 treatment known to cause liver toxicity, thereby improving liver function. It can be usefully used as a dietary supplement or health supplement food.
이하 본 발명을 실시예 및 실험예 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
<< 실시예Example 1> 1> 블랙베리Blackberry (( RubusRubus fruticosusfruticosus L. L. ) 식초의 제조Manufacture of Vinegar
<1-1> <1-1> 블랙베리Blackberry 식초 재료의 준비 Preparation of Vinegar Ingredients
블랙베리(blackberry mayple)는 2008 ~ 2009년 7월 전남 장흥군에서 수확한 것을 구입하여 -20℃ 냉동고에 저장하면서 실온에서 해동시킨 후 일정량을 취해 블랙베리 발효제조용으로 사용하였으며 믹서기로 파쇄한 것을 원료로 사용하였다.
Blackberry mayple was harvested from Jangheung-gun, Jeonnam, Korea in July, 2009, and stored in a -20 ℃ freezer, thawed at room temperature, and then used to produce blackberry fermentation. Used.
<1-2> 사용 균주의 제조<1-2> Preparation of Strains Used
알코올발효 균주는 한국생명자원센터에서 분양받은 사카로미세스 세레비시아(Saccharomyces cerevisiae; KCTC 7904)을 YPD 평판배지에 계대 배양한 후, YM 액체배지에서 24℃에서 24시간 정치 배양하여 사용하였다. 또한, 초산균은 경북과학대학 전통식품연구소에서 보관중인 아세토박터 종. PA 97(Acetobacter sp . PA 97)을 0.5% 효모 추출물(yeast extract), 0.5% 글루코스(glucose), 1.0% 글리세린(glycerin), 0.02% MgSO4 ·7H2O, 5.0% 에탄올(ethanol), 1.0% 아세트산(acetic acid)의 배지 조성으로 30℃에서 72시간 배양하여 사용하였다.
Alcohol fermentation strains were Saccharomyces cerevisiae ; KCTC 7904) was passaged in a YPD plate medium, and then used for 24 hours incubation at 24 ° C. in a YM liquid medium. In addition, acetic acid bacteria are acetobacter species stored at the Institute of Traditional Foods, Kyungpook National University of Science. PA 97 (Acetobacter sp. PA 97 ) with 0.5% yeast extract (yeast extract), 0.5% glucose (glucose), 1.0% glycerol (glycerin), 0.02% MgSO 4 · 7H 2 O, 5.0% ethanol (ethanol), 1.0 Incubated at 30 ° C. for 72 hours as a medium composition of% acetic acid.
<1-3> 주모 및 <1-3> master and 종초배양Seed culture
주모는 블랙베리를 파쇄하여 가수한 후 100% 과당(fructose)(73°brix)으로 당도를 15°brix로 조절한 사카로미세스 세레비시아를 접종하여 25℃에서 48시간 정치배양하여 사용하였으며, 종초는 주모 제조시와 동일한 방법으로 제조된 블랙베리 알코올 발효액을 여과한 후, 그 여액을 초산균주 아세토박터 종. PA 97(Acetobacter sp. PA97)를 접종하여 30℃에서 200 rpm으로 72시간 진탕 배양하여 사용하였다.
Jumo crushed blackberry and then inoculated with 100% fructose (73 ° brix) and inoculated with Saccharomyces cerevisiae with the sugar content adjusted to 15 ° brix and incubated at 25 ° C for 48 hours. Seeds were filtered using a blackberry alcohol fermentation broth prepared in the same manner as in the preparation of the seedlings, and the filtrate was extracted from Acetobacter sp. PA 97 ( Acetobacter sp. PA97) was inoculated and used for 72 hours shaking culture at 200 ° C. at 200 rpm.
<1-4> <1-4> 블랙베리Blackberry 식초의 제조 Vinegar
블랙베리 식초를 제조하기 위하여, 2단계 발효를 진행하였다. 알코올발효는 믹서기로 파쇄한 블랙베리 파쇄액과 보당액인 사과 농축액(경북능금협동조합, 한국)을 이용하여 초기 당도를 15°brix이 되도록 농도를 맞춰 초산발효를 위한 알코올 발효에 가장 적합한 기질을 만들었다. 블랙베리 파쇄액 30%(V/V), 사과 농축액 16.6%(V/V) 및 정제수 53.4%(V/V)가 혼합된 원액에 접종하는 주모의 양은 5%(V/V)를 접종하였고, 알코올 발효가 가장 잘 일어나는 25℃의 배양온도에서 4일간 정치 배양하였다. 배양시 초산발효에 적절한 알코올 함량인 7.4%대에 도달할 때까지 일정하게 상기 상태를 유지하였다. 알코올 발효가 끝난 블랙베리주를 5,000 rpm에서 20분간 원심분리하여 상등액만을 취하여 0.45 ㎛ 필터(filter)에 통과시켜 찌꺼기를 제거하여 초산발효 기질로 사용하였다. 상기와 같이 처리된 블랙베리주를 공기와의 접촉이 용이한 500 mL 삼각 플라스크(flask)에 100 mL을 넣고 상기 실시예 <1-3>에서 제조한 종초를 블랙베리주 부피 대비 10%를 접종하여, 초산 발효시 필요한 초기 알코올 농도 7.4%와 초기산도 1%로 맞춘 후, 30℃에서 200 rpm으로 72시간 진탕 배양하면서 산도 및 알코올 함량의 측정한 결과, 20일째 최종산도 6.6%, 잔류 알코올 함량은 0%로 우리 나라의 산업자원부 기술표준원에서 정한 과실 식초의 조건을 만족하는 블랙베리 식초 6 g을 제조하였다(도 1).
To prepare blackberry vinegar, two-step fermentation was performed. Alcohol fermentation is performed using a blended blackberry crushed solution and apple concentrate (Kyongbuk Neungpung Cooperative, South Korea) to adjust the initial sugar concentration to 15 ° brix to obtain the most suitable substrate for alcoholic fermentation for acetic acid fermentation. made. 5% (V / V) of the seedlings were inoculated into the stock solution containing 30% of the black crushed juice (V / V), 16.6% of the apple concentrate (V / V), and 53.4% (V / V) of purified water. Incubated for 4 days at a culture temperature of 25 ℃ the alcohol fermentation is best. The culture was constantly maintained until reaching 7.4%, an alcohol content suitable for acetic acid fermentation. The alcoholic fermented blackberries were centrifuged at 5,000 rpm for 20 minutes, and only the supernatant was taken through a 0.45 μm filter to remove debris and used as an acetic acid fermentation substrate. 100 ml of the blackberry wine treated as described above was put in a 500 mL Erlenmeyer flask (flask) which is easily in contact with air, and the seed vinegar prepared in Example <1-3> was inoculated with 10% of the volume of the blackberry wine. After adjusting the initial alcohol concentration of 7.4% and the initial acidity of 1% necessary for acetic acid fermentation, the acidity and alcohol content were measured while shaking culture at 30 ° C. at 200 rpm for 72 hours.
<< 실시예Example 2> 2> 블랙베리Blackberry 식초를 함유하는 음료 조성물의 제조 Preparation of Drink Compositions Containing Vinegar
블랙베리 식초를 함유하는 음료를 제조하기 위하여, 하기 [표 1]에 기재된 배합비로 혼합한 후, 50℃에서 30분간 교반한 후, 상기 배압된 액을 5μ필터로 1차 여과한 다음, 98℃ 고온단시간살균법(High temperature short time, HTST)을 수행하여 살균한 후, 5μ필터를 이용하여 2차 여과를 수행하였다. 그런 다음, 상기 살균 및 여과된 액을 자동 충진기에서 75 ml 병에 90℃가 유지되도록 하여 충진한 후, 냉각기에서 40 ~ 45℃까지 냉각시켜 최종적으로 20℃에서 12°brix, 25℃에서 pH 3.1 및 산도(Acidity) 0.29인 블랙베리 식초를 함유하는 음료 조성물을 제조하였다. In order to prepare a beverage containing blackberry vinegar, after mixing at the mixing ratio shown in the following [Table 1], and stirred at 50 ℃ for 30 minutes, the back pressure liquid was first filtered with a 5μ filter, and then 98 ℃ After sterilization by high temperature short time (HTST), secondary filtration was performed using a 5μ filter. Then, the sterilized and filtered liquid was filled in a 75 ml bottle in an automatic filler to maintain 90 ℃, and then cooled to 40 ~ 45 ℃ in the cooler finally at 12 ° brix at 20 ℃, pH at 25 ℃ A beverage composition was prepared containing the blackberry vinegar with 3.1 and Acidity 0.29.
이때, 상기 사용한 모든 재료는 식품첨가물 공전 규격에 적합한 원료만을 검수하여 사용하였으며, 정제수는 물을 RO 여과기를 통과시켜 정수한 정제수를 사용하였다.
At this time, all the materials used were inspected and used only raw materials that meet the food additives orbital standards, and purified water was used purified water by passing the water through a RO filter.
(경북능금협동조합,한국)Apple Juice Concentrate
(Gyeongbuk Neungkum Cooperative, Korea)
((주)대평, 한국)Enzyme Treatment Stevia
(Daepyeong, Korea)
<< 실험예Experimental Example 1> 1> CClCCl 44 유도된 간 손상 동물 모델의 제조 Preparation of Induced Liver Injury Animal Models
<1-1> 실험동물의 사육<1-1> Breeding of Experimental Animals
6 주령의 수컷 Sprague-Dawley 랫트(150 ± 10 g)(오리엔트바이오, 한국)은 표준 환경 조건에서 1주일간 순응시키며, 표준식이와 물을 자유식이로 섭취하게 하였다. 상기 랫트는 12/12시간의 명-암 주기로 에어컨디션 방에서 유지하였다. 또한, 본 발명에서 사용한 모든 실험 프로토콜은 한국 원자력 연구원의 동물 실험윤리위원회(KAERI-IACUC)에서 인증된 실험 동물 관리 및 이용 가이드라인에 따라 수행하였다.
Six-week-old male Sprague-Dawley rats (150 ± 10 g) (Oriental Bio, Korea) were allowed to acclimate for one week under standard environmental conditions and were given a free diet of standard diet and water. The rats were maintained in an air conditioning room with a light-dark cycle of 12/12 hours. In addition, all experimental protocols used in the present invention were carried out in accordance with the guidelines for management and use of experimental animals certified by KAERI-IACUC.
<1-2> <1-2> CClCCl 44 유도 급성 간 독성 Induced Acute Liver Toxicity 랫트의Rat 제조 Produce
6주령 랫트를 임의로 한 그룹당 7마리로, 4그룹으로 나누었다: Six-week-old rats were randomly divided into seven groups per group and divided into four groups:
그룹 1) 올리브 오일(olive oil) 및 식염수 공급; Group 1) olive oil and saline feed;
그룹 2) CCl4 1 g/kg 및 식염수 공급;Group 2) CCl 4 1 g / kg and saline feed;
그룹 3) CCl4 1 g/kg 및 본 발명의 음료 조성물 3 ㎖/㎏ 공급; 및 Group 3) CCl 4 Feeding 1 g / kg and 3 ml / kg of the beverage composition of the invention; And
그룹 4) CCl4 1 g/kg 및 본 발명의 음료 조성물 6 ㎖/㎏ 공급.Group 4) CCl 4 Feed 1 g / kg and 6 ml / kg of the beverage composition of the invention.
상기 <실시예 2>에서 제조한 본 발명의 음료 조성물을 직접 랫트에 투여하였으며, 50% CCl4는 올리브 오일에서 제조하었다. 본 발명의 음료 조성물은 15일 동안, 600(3 ㎖/㎏) 및 1200 ㎕(6 ㎖/㎏) 씩 하루에 한번 구강으로 투여하였다. 그룹1) 및 2)는 본 발명의 음료 조성물 투여군과 동일하게 식염수를 15일 동안 하루에 한번 구강으로 투여하였다. 마지막 경구투여 3시간 후, 랫트에 올리브 오일을 이용하여 제조한 CCl4 300 ㎕를 복강으로 투여하였다. 그룹1)은 올리브 오일만 300 ㎕를 복강으로 투여하였다. 그 후, 18시간 동안 절식하였으며, 이의 산화스트레스 및 간 보호효과를 확인하는 실험을 수행한 후, 모든 랫트를 안락사시켰다. 혈액은 혈청의 아스파라진산 아미노전이효소(Aspartate Aminotransferase, AST) 및 알라닌 아미노전이효소(alanine aminotransferase, ALT) 활성을 측정하기 위하여, 에테르(ether)를 이용하여 상기 랫트를 마취시킨 후, 후대 정맥(postcaval vein)으로부터 채취하였다. 또한, 상기 랫트의 간을 신속하게 채취하여, 항산화 효소 분석에 사용하였다.
The beverage composition of the present invention prepared in Example 2 was directly administered to rats, and 50% CCl 4 was prepared in olive oil. The beverage composition of the present invention was administered orally once a day for 600 (3 ml / kg) and 1200 µl (6 ml / kg) for 15 days. Groups 1) and 2) were orally administered saline once a day for 15 days in the same manner as the beverage composition administration group of the present invention. 3 hours after the last oral administration, CCl 4 was prepared using olive oil in the rat. 300 μl was administered intraperitoneally. Group 1) received 300 μl of olive oil intraperitoneally. Thereafter, the rats were fasted for 18 hours, and all rats were euthanized after an experiment to confirm their oxidative stress and hepatoprotective effects. The blood was anesthetized with rats using ether to measure serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity. postcaval vein). In addition, livers of the rats were rapidly collected and used for antioxidant enzyme analysis.
<< 실험예Experimental Example 2> 2> CClCCl 44 유도 급성 간 독성 Induced Acute Liver Toxicity 랫트에서의In rats 블랙베리Blackberry 식초를 함유하는 음료 조성물의 산화 스트레스에 대한 보호효과 확인 Identification of protective effect against oxidative stress of beverage compositions containing vinegar
본 발명의 음료 조성물의 상기 <실험예 1>에서 제조한 CCl4 유도 급성 간 독성 랫트에서의 산화 스트레스에 대한 보호효과를 측정하기 위하여 Cayman Chemical에서 구입한 키트를 이용하여 황산화 효소인 GPx의 활성을 측정하였다. CCl 4 prepared in the above <Experimental Example 1> of the beverage composition of the present invention Induced acute hepatotoxicity To determine the protective effect against oxidative stress in rats, the activity of the sulfated enzyme GPx was measured using a kit purchased from Cayman Chemical.
구체적으로 상기 실험예 <1-2>의 4개 군의 CCl4 유도 급성 간 독성 랫트로부터 채취한 간 조직 100 ㎎에 1 ㎖의 라이시스(lysis) 버퍼를 첨가하고 호모지나이저(homogenizer)로 분쇄한 후 10000 g, 4℃에서 원심분리하여 조직 현탁액을 준비하였다. GPx 분석 키트에 포함된 100 ㎕의 에세이(Assay) 버퍼에 50 ㎕의 공통 기질 혼합물(co-substrate mixture)과 20 ㎕의 조직 현탁액을 혼합하고 20 ㎕의 큐멘 하이드로퍼옥사이드(cumene hydroperoxide)를 첨가한 후 분광광도계를 이용하여 340 ㎚에서 흡광도를 측정하여 GPx 농도를 계산하였다. Specifically, CCl 4 of the four groups of Experimental Example <1-2> Induced
그 결과, 도 2에 나타난 바와 같이, 항산화 효소인 GPx의 활성이 CCl4 유도 급성 간 독성 랫트의 간에서 CCl4를 투여하지 않은 대조군 랫트에 비하여 감소하는 것을 확인하였다. 그러나, 본 발명의 음료 조성물을 미리 투여한 후, CCl4를 투여하여 제조한 간 독성 랫트에서는 GPx의 활성이 대조군에 비하여 유의하게 증가하는 것을 확인하였다(도 2).
As a result, as shown in Figure 2, the activity of the antioxidant enzyme GPx is CCl 4 Induced Acute Liver Toxicity In Rats Untreated with CCl 4 It was confirmed that the decrease compared to the control rat. However, after pre-administration of the beverage composition of the present invention, it was confirmed that the hepatotoxicity rats prepared by administering CCl 4 significantly increased the activity of GPx compared to the control group (FIG. 2).
<< 실험예Experimental Example 3> 3> CClCCl 44 유도 급성 간 독성 Induced Acute Liver Toxicity 랫트에서의In rats 블랙베리Blackberry 식초를 함유하는 음료 조성물의 간 보호효과 확인 Confirmation of liver protection effect of beverage composition containing vinegar
CCl4에 의한 간 손상은 세포막의 투과성(permeability)을 증가시키고, 간에서 혈액으로 급성 간 손상의 표지로 알려진 아스파진산 아미노전이효소(Aspartate Aminotransferase, AST)와 아미노전이효소(Alanine Aminotransferase, ALT)를 분비시킨다(Adesanoye, O.A., et al., Experimental and Toxicologic Pathology, 2010; Ranawat, L., et al., Journal of Ethnopharmacology, 2010). 이에, 본 발명자들은 혈청 AST와 ALT의 수준을 간 손상의 지표로서 측정하였다. 구체적으로, AST와 ALT의 수준은 임상 생화학 자동 분석기(biochemistry automatic analyzer)(Hitachi Model 7180, 일본)를 이용하여 측정하였다.Liver damage caused by CCl 4 increases cell membrane permeability, and aspartate aminotransferase (AST) and aminotransferase (ALT), known as markers of acute liver damage from liver to blood. Secrete (Adesanoye, OA, et al., Experimental and Toxicologic Pathology , 2010; Ranawat, L., et al., Journal of Ethnopharmacology , 2010). Thus, we measured the levels of serum AST and ALT as indicators of liver damage. Specifically, the levels of AST and ALT were measured using a clinical biochemistry automatic analyzer (Hitachi Model 7180, Japan).
그 결과, 도 3에 나타난 바와 같이, CCl4 유도 급성 간 독성 랫트에서는 독성을 유발하지 않은 대조군 랫트에 비하여 AST와 ALT의 수준이 현저하게 증가하는 것을 확인하였다. 그런, 본 발명에 따른 음료 조성물(3 또는 6 ㎖/㎏)을 미리 투여한 후, CCl4를 투여하여 제조한 간 독성 랫트에서는 AST와 ALT의 수준이 현저하게 감소하는 것을 확인하였다(도 3).
As a result, as shown in Figure 3, the CCl 4 induced acute liver toxicity rats were confirmed to significantly increase the levels of AST and ALT compared to control rats that did not induce toxicity. Such, after administration of the beverage composition (3 or 6 ml / kg) according to the present invention in advance, it was confirmed that the level of AST and ALT is significantly reduced in liver toxicity rat prepared by administering CCl 4 (Fig. 3). .
Claims (11)
2) 상기 단계 1)의 혼합하여 교반된 액을 1차 여과하는 단계;
3) 단계 2)의 여과된 액을 살균한 후, 2차 여과하는 단계를 포함하는 블랙베리 식초를 함유하는 간 기능 개선용 음료 조성물의 제조방법.
1) Blackberry ( Rubus fruticosus L. ) 4 to 10 parts by weight of vinegar, 0.5 to 3 parts by weight of blackberry concentrate, 0.5 to 3 parts by weight of apple concentrate, 6 to 15 parts by weight of liquid fructose, 1 to 5 parts by weight of flacto oligosaccharides, enzymatically treated stevia 0.0001 to Stirring by mixing 0.020 parts by weight, citric acid 0.1 to 0.5 parts by weight, lotus leaf extract 0.01 to 0.1 parts by weight, raspberry flavor 0.01 to 0.1 parts by weight, and purified water 70 to 90 parts by weight;
2) filtering the stirred solution by mixing of step 1);
3) After sterilizing the filtered liquid of step 2), the method for producing a beverage composition for improving liver function containing the black vinegar comprising the step of secondary filtration.
1) 블랙베리 파쇄액 25 내지 35 중량부, 사과농축액 10 내지 20 중량부 및 정제수 50 내지 60 중량부를 혼합하여 초기 당도를 10 내지 20°brix으로 조정하고 효모를 접종하여 알코올 발효시키는 단계; 및
2) 상기 단계 1)의 알코올 발효물은 여과한 후, 알코올 농도 5 내지 9%로 조정하고 초산균을 접종하여 초산 발효시키는 단계.
The method according to claim 1, wherein the blackberry vinegar of step 1) is prepared by a method comprising the following steps:
1) mixing 25 to 35 parts by weight of black crushed liquor, 10 to 20 parts by weight of apple concentrate and 50 to 60 parts by weight of purified water to adjust the initial sugar to 10 to 20 ° brix and inoculate yeast to ferment alcohol; And
2) after the alcohol fermentation of step 1) is filtered, the alcohol concentration is adjusted to 5 to 9% and inoculated with acetic acid bacteria to ferment acetic acid.
According to claim 2, wherein the alcohol fermentation of step 1) is Saccharomyces cerevisiae ( Saccharomyces cerevisiae ; KCTC 7904) 1 to 10 parts by weight of the inoculation and a method for producing a beverage composition for improving liver function containing black vinegar, characterized in that the culture for 2 to 6 days at 20 to 30 ℃.
The acetic acid fermentation of claim 2, wherein the acetic acid fermentation of step 2) is acetobacter species. PA 97 ( Actobacter sp . PA 97) inoculated 5 to 20 parts by weight and a method for producing a beverage composition for improving liver function containing blackberry vinegar, characterized in that incubated for 10 to 25 days at 25 to 35 ℃.
The method of claim 2, wherein the acidity of acetic acid fermentation prepared in step 2) is 0.5 to 2%.
According to claim 1, wherein in step 1) 5 to 7 parts by weight of blackberry vinegar, 0.7 to 1.5 parts by weight of blackberry concentrate, 0.7 to 1.5 parts by weight of apple concentrate, 9 to 11 parts by weight of liquid fructose, 2 to about flacto oligosaccharides 4 parts by weight, enzyme-treated stevia 0.008 to 0.012 parts by weight, citric acid 0.2 to 0.4 parts by weight, lotus leaf extract 0.03 to 0.07 parts by weight, raspberry flavor 0.03 to 0.07 parts by weight and purified water 75 to 85 parts by weight Method for producing a beverage composition for improving liver function containing vinegar.
The method of claim 1, wherein the stirring of step 1) is carried out at 45 to 55 ° C. for 20 to 40 minutes.
The method of claim 1, wherein the primary filtration and the secondary filtration is a method of producing a beverage composition for improving liver function, containing black vinegar, characterized in that the filtration with a 3 to 7 μ filter respectively.
The method according to claim 1, wherein the sterilization of step 3) is performed for 20 to 40 seconds at 90 to 110 ° C.
The liver containing blackberry vinegar according to claim 1, further comprising the step of filling the secondary filtrate of step 3) to maintain 80 to 95 ° C and cooling it to 35 to 50 ° C in a cooler. Method for producing a beverage composition for improving function.
Drink composition for improving liver function containing the black vinegar prepared by the method of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110105353A KR101314829B1 (en) | 2011-10-14 | 2011-10-14 | Liver protecting beverage containing blackberry vinegar and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110105353A KR101314829B1 (en) | 2011-10-14 | 2011-10-14 | Liver protecting beverage containing blackberry vinegar and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130040524A true KR20130040524A (en) | 2013-04-24 |
KR101314829B1 KR101314829B1 (en) | 2013-10-04 |
Family
ID=48440327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110105353A Expired - Fee Related KR101314829B1 (en) | 2011-10-14 | 2011-10-14 | Liver protecting beverage containing blackberry vinegar and its preparing method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101314829B1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103387928A (en) * | 2013-08-04 | 2013-11-13 | 彭常安 | Processing method of blackberry phyllanthus emblica fruit vinegar |
CN103789187A (en) * | 2014-01-17 | 2014-05-14 | 青岛琅琊台集团股份有限公司 | Method for making isomaltulose vinegar |
CN103892381A (en) * | 2014-03-24 | 2014-07-02 | 彭聪 | Processing method of blackberry fruit vinegar drink |
CN103948097A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Fructose phyllanthus emblica fruit vinegar beverage and processing method thereof |
CN103948096A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Fruit vinegar beverage having effects of dispelling effects of alcohol and protecting liver and processing method thereof |
CN103948098A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Composite fruit vinegar beverage and processing method thereof |
CN104312896A (en) * | 2014-11-03 | 2015-01-28 | 徐州工程学院 | Compound fruit vinegar and preparing method thereof |
KR20160012542A (en) * | 2014-07-24 | 2016-02-03 | 윤정란 | Method for producing drink including composition obtained by acetic acid fermentation composition using Sea Buckthorn and the drink thereby |
CN108651793A (en) * | 2018-04-26 | 2018-10-16 | 江苏惠田农业科技开发有限公司 | A kind of production method of the compound blackberry drink rich in exocellular polysaccharide |
KR20200001803A (en) * | 2018-06-28 | 2020-01-07 | 농업회사법인 주식회사 생생초 | Method for manufacturing drink including pinus densiflora fermentation vinegar and lactic acid bacteria fermented liquor, and the drink manufactured by the method |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160074939A (en) | 2014-12-19 | 2016-06-29 | 농업회사법인 주식회사 담양블루베리 | A method of preparing blueberry tea |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR920005920A (en) * | 1990-09-24 | 1992-04-27 | 함태호 | Functional drink and its manufacturing method |
KR970032514A (en) * | 1995-12-21 | 1997-07-22 | 성재갑 | Brush vinegar and a beverage composition containing the same |
KR20060011914A (en) * | 2006-01-19 | 2006-02-03 | (주)케어메딕스 | Functional food composition for hangover and its manufacturing method |
KR100900343B1 (en) | 2007-07-05 | 2009-06-02 | 조선대학교산학협력단 | A composition for the prevention and treatment of liver disease, which contains a venom active extract that has cytotoxicity and inhibits liver damage. |
-
2011
- 2011-10-14 KR KR1020110105353A patent/KR101314829B1/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103387928A (en) * | 2013-08-04 | 2013-11-13 | 彭常安 | Processing method of blackberry phyllanthus emblica fruit vinegar |
CN103789187A (en) * | 2014-01-17 | 2014-05-14 | 青岛琅琊台集团股份有限公司 | Method for making isomaltulose vinegar |
CN103948097A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Fructose phyllanthus emblica fruit vinegar beverage and processing method thereof |
CN103948096A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Fruit vinegar beverage having effects of dispelling effects of alcohol and protecting liver and processing method thereof |
CN103948098A (en) * | 2014-03-19 | 2014-07-30 | 桂玉平 | Composite fruit vinegar beverage and processing method thereof |
CN103948096B (en) * | 2014-03-19 | 2015-11-18 | 桂玉平 | A kind of relieving alcoholism and protecting liver Health-care fruit vinegar beverage and processing method thereof |
CN103892381A (en) * | 2014-03-24 | 2014-07-02 | 彭聪 | Processing method of blackberry fruit vinegar drink |
KR20160012542A (en) * | 2014-07-24 | 2016-02-03 | 윤정란 | Method for producing drink including composition obtained by acetic acid fermentation composition using Sea Buckthorn and the drink thereby |
CN104312896A (en) * | 2014-11-03 | 2015-01-28 | 徐州工程学院 | Compound fruit vinegar and preparing method thereof |
CN108651793A (en) * | 2018-04-26 | 2018-10-16 | 江苏惠田农业科技开发有限公司 | A kind of production method of the compound blackberry drink rich in exocellular polysaccharide |
KR20200001803A (en) * | 2018-06-28 | 2020-01-07 | 농업회사법인 주식회사 생생초 | Method for manufacturing drink including pinus densiflora fermentation vinegar and lactic acid bacteria fermented liquor, and the drink manufactured by the method |
Also Published As
Publication number | Publication date |
---|---|
KR101314829B1 (en) | 2013-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101314829B1 (en) | Liver protecting beverage containing blackberry vinegar and its preparing method | |
KR101183605B1 (en) | The beverage composition for anti-hangover functional using cucumber vinegar | |
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
KR19990014205A (en) | Compositions Containing Flavonoids and Papia Workpieces | |
KR20180061062A (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
TWI430754B (en) | Method for producing high γ-aminobutyric acid-containing material | |
KR101799455B1 (en) | Method for manufacturing the functional drink used the mixing extracts of Inonotus obliquus, Phellinus linteus and Sparassis crispa and its functional drink | |
KR20190138066A (en) | kombucha manufacturing method | |
KR101302652B1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS COMPRISING α-GLUCOSIDASE INHIBITOR AND BREWER'S DRIED YEAST | |
KR20200045116A (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR101819026B1 (en) | Composition for use of inhibition of stomach damage to alcohol or inhibition of alcohol uptake or relief of hangover comprising fermented extract of native plants from Jeju island | |
CN117717131A (en) | Turmeric and hericium erinaceus compound beverage and preparation method thereof | |
CN102099049B (en) | Natrual inhibitor of the enzymatic production of 3-deoxy-glucosone | |
KR20150087724A (en) | Composition containing Artemisia annua extract antioxidant | |
JP2006075083A (en) | Fermented product obtained from balsam pear | |
KR102437419B1 (en) | Composition for removing hangover | |
KR20180042936A (en) | a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover | |
KR101034986B1 (en) | Hangover relief composition containing mixed herbal extracts as an active ingredient | |
EP4458940A1 (en) | Method for preparing fermented hovenia dulcis thunb having hangover relief and liver protection effects, and beverage composition prepared using same as main ingredient | |
KR20090043758A (en) | Fatty liver improver composition | |
KR20150110116A (en) | The manufacture method of functional wine using mallotus japonicus fermented liquor. | |
KR20180098882A (en) | Composition for the effect of suppressing the elevation of blood sugar level having extract of peanut sprouts as active component | |
KR100526164B1 (en) | Composition for enhancing exercise performance | |
KR20090098254A (en) | Method of producing mugwort concentrate using fermentation | |
JP2007097500A (en) | Method for producing salacia reticulata-containing health food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20111014 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130319 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130923 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130927 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130930 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20160607 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20160607 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190916 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20190916 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20200914 Start annual number: 8 End annual number: 8 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20220708 |